...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Frontiers in Neurology >Long-term Monitoring Gait Analysis Using a Wearable Device in Daily Lives of Patients with Parkinson’s Disease: The Efficacy of Selegiline Hydrochloride for Gait Disturbance
【24h】

Long-term Monitoring Gait Analysis Using a Wearable Device in Daily Lives of Patients with Parkinson’s Disease: The Efficacy of Selegiline Hydrochloride for Gait Disturbance

机译：使用可穿戴设备对帕金森氏病患者的日常生活进行长期监测步态分析：盐酸司来吉兰对步态干扰的功效

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective The aim of this study was to assess quantitatively the gait disorders in the daily lives of patients with Parkinson’s disease (PD) using with a newly developed portable gait rhythmogram (PGR), which has a trunk-mounted acceleration sensor and automatic gait-detection algorithm. Methods Using the PGR, we recorded the daily walking profiles of 14 PD patients before and after the addition or increase in dose of an MAO-B inhibitor (selegiline, average dose: 4.0?mg/day) as part of their medicine regimen, and evaluated their gait using the unified Parkinson’s disease rating scale (UPDRS) and scores from a freezing of gait (FOG) questionnaire. Results Before treatment with selegiline, the overall movements per 24?h was decreased below 0.41?m/s~(2)(mean???1.5 SD) in eight patients. The mean gait acceleration was decreased below 1.94?m/s~(2)(mean???2 SD) in 10 patients. The slope of the linear regression line was increased to 1.6 (mean?+?1.5 SD) in eight patients. The cadence was increased to 124?steps/min (mean?+?1.5 SD) in four patients. Based on continuous PGR recordings in the daily lives of the patients for 24?h, the addition or increase in dose of selegiline increased the amplitudes of gait accelerations in 4 of 10 patients (40.0%), widened the range of gait accelerations in 5 of 8 patients (62.5%), diminished the cadence in 4 of 4 patients (100%), and diminished the fluctuations in gait throughout the day in 12 of 14 patients (85.7%). The UPDRS III and FOG scores significantly improved after the addition or increase in dose of selegiline ( p ?
机译：目的本研究的目的是使用新开发的便携式步态心律图（PGR）定量评估帕金森病（PD）患者日常生活中的步态障碍，该步态图具有躯干安装式加速度传感器和自动步态检测功能算法。方法使用PGR记录了14例PD患者在药物治疗方案中添加或增加MAO-B抑制剂剂量（司来吉兰，平均剂量：4.0？mg /天）前后的每日行走情况，以及使用统一的帕金森氏病评分量表（UPDRS）评估他们的步态，并通过步态冻结问卷（FOG）评估得分。结果在使用司来吉兰治疗之前，八名患者每24？h的总体运动降低到0.41？m / s〜（2）（平均1.5 SD）以下。 10名患者的平均步态加速度降低到1.94？m / s〜（2）（平均2 SD）以下。八名患者的线性回归线的斜率增加到1.6（均值±1.5 SD）。 4名患者的节奏被提高到124步/分钟（平均s + 1.5 SD）。根据患者24小时的日常PGR记录，增加或增加司来吉兰的剂量会增加10名患者中4名的步态加速幅度（40.0％），扩大了5名患者中步态加速的幅度8例患者（62.5％），4例患者中的4例（100％）的节奏降低了，并且14例患者中的12例（85.7％）的全天步态波动减小了。司来吉兰的剂量增加或增加后，UPDRS III和FOG评分显着改善（分别为p 0.005，p 0.01）。但是，在6例患者中未发现步态相关的UPDRS评分变化。结论在患者24小时的日常生活中，使用PGR可以显着改善司来吉兰添加或剂量增加后PD患者的步态波动。与UPDRS评分相比，PGR对改进的检测灵敏度更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号